Nesvacumab is an experimental monoclonal antibody originally designed for the treatment of cancer. It targets the protein angiopoietin 2.Statement On A Nonproprietary Name Adopted By The USAN Council - Nesvacumab, American Medical Association. , the drug was in Phase II clinical trials for the treatment of diabetic macular edema.
This drug is being developed by Regeneron Pharmaceuticals.
References